No Data
No Data
Phathom to Showcase Real-World Data for VOQUEZNA Heartburn Treatment at Major GI Conference
Earnings Preview: PHAT to Report Financial Results on May 01
Phathom Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide Business Update on Thursday, May 1, 2025
Phathom Pharmaceuticals Is Maintained at Neutral by Goldman Sachs
Goldman Sachs Maintains Phathom Pharmaceuticals(PHAT.US) With Hold Rating, Cuts Target Price to $10
Express News | Phathom Pharmaceuticals Appoints Ted Schroeder to Its Board of Directors
PYUN970IHaveChosen OP : Work the numbers not the system!
TheFather : Just keeps on giving back
PYUN970IHaveChosen OP TheFather : That’s how your system works!!!
The Father! GL to All
!
Xyno : you bought for 2.47? when was the price that low?
PYUN970IHaveChosen OP Xyno : No,no, that is my diluted cost. I have been holding for sometime! GL to ALL
!